Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy5
Outperform7
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 10 analysts offering 12 month price targets for AstraZeneca plc (ADR) have a median target of 90.55, with a high estimate of 103.00 and a low estimate of 75.50. The median estimate represents a 40.91% increase from the last price of 64.26.
High60.3%103.00
Med40.9%90.55
Low17.5%75.50

Dividends in USD

Historical dividend information is not available for AstraZeneca PLC.
Div growth (TTM)--
More ▼

Earnings history & estimates in USD

On Nov 12, 2024, AstraZeneca plc (ADR) reported 3rd quarter 2024 earnings of 1.04 per share. This result was in line with the consensus of the 3 analysts following the company and exceeded last year's 3rd quarter results by 19.54%.
The next earnings announcement is expected on Feb 06, 2025.
Average growth rate+6.64%
AstraZeneca plc (ADR) reported annual 2023 earnings of 3.63 per share on Feb 08, 2024.
Average growth rate+20.34%
More ▼

Revenue history & estimates in USD

AstraZeneca plc (ADR) had 3rd quarter 2024 revenues of 13.57bn. This bettered the 13.09bn consensus of the 5 analysts covering the company. This was 24.69% above the prior year's 3rd quarter results.
Average growth rate+4.24%
AstraZeneca plc (ADR) had revenues for the full year 2023 of 45.81bn. This was 3.29% above the prior year's results.
Average growth rate+17.89%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.